Egyptian Drug Authority

What Egyptian Drug Authority does

The Egyptian Drug Authority (EDA) is Egypt's national regulatory authority for pharmaceuticals, biological products, and medical devices, established by Law No. 151 of 2019 as a public service body with legal personality affiliated with the Prime Minister. Operating from six physical offices across Cairo, Giza, and the New Administrative Capital, the authority oversees drug registration, licensing, inspection, pharmacovigilance, and quality control for the Egyptian pharmaceutical market—a context where Egypt achieves approximately 91% drug self-sufficiency and contributes more than half of Africa's pharmaceutical exports. EDA's mandate spans central administrations covering pharmaceutical products, biological and innovative products and clinical trials, medical devices, pharmaceutical care, drug control, and pharmaceutical institution licensing.

EDA operates a portfolio of digital regulatory platforms including the Digital Platform for Protocol Management and Clinical Trials, the Drug Tracking System, the EVERS pharmacovigilance reporting system, the Bio-Release batch certification system, the MeDevice portal for medical device registration, EGYCOSMA for cosmetics, and supporting services for pricing inquiries, naming checks, variation submissions, factory/warehouse searches, and inspection reports. The authority also maintains the Egyptian Pharmacopoeia, now in its fifth edition (2024) with over 3,000 monographs serving as the first regional pharmaceutical reference with international specifications. A Center for Continuing Professional Development, established October 2020, provides workforce training and has been designated a WHO Regional Training Centre for Biomanufacturing for the Eastern Mediterranean region.

EDA operates as a non-commercial government entity under direct governmental oversight, providing all regulatory services free of charge and funded through public budget allocations. Its service interfaces are designed for enterprise users—pharmaceutical manufacturers, importers, pharmacy establishments, medical device companies, and healthcare professionals—delivered through office networks, digital self-serve portals, and a national hotline (15301). Commercial revenue is not generated; instead, the authority produces institutional influence and trade-facilitation benefits through bilateral MoUs with African regulatory authorities, observer and full memberships in the European Pharmacopoeia Commission and US Pharmacopeia Convention respectively, and an agreement to host the operational headquarters of the African Pool Procurement Mechanism with Africa CDC.

Name

Egyptian Drug Authority

Legal name

Egyptian Drug Authority (EDA) - هيئة الدواء المصرية

Website

https://edaegypt.gov.eg

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The Egyptian Drug Authority is Egypt's national regulatory body overseeing pharmaceuticals, biological products, and medical devices through registration, licensing, inspection, pharmacovigilance, and digital e-services, serving manufacturers, importers, pharmacies, and healthcare professionals.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Services

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615), Administration of Public Health Programs (923120)

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

Keywords

• Pharmaceutical regulatory services
• Drug registration oversight
• Medical device regulation
• Pharmacovigilance monitoring
• National pharmacopoeia standards

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Regulatory Services: As a public regulatory authority, the Egyptian Drug Authority provides regulatory services including drug registration, licensing, inspection, and pharmacovigilance. Services are provided as public function under government mandate, with costs covered through government budget allocations.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

The Egyptian Drug Authority (EDA) is Egypt's national regulatory authority for pharmaceutical products and medical devices, operating under Law No. 151 of 2019 and affiliated with the Prime Minister. It provides regulatory oversight including drug registration, licensing of pharmaceutical establishments, medical device approvals, pharmacovigilance, inspection, batch release for biological products, and maintains the official Egyptian Pharmacopoeia. It delivers these services through a digital e-services portal, six physical offices across Egypt, and a unified hotline (15301).

Product overview

The Egyptian Drug Authority (EDA) operates as Egypt's national pharmaceutical regulatory body, offering a comprehensive suite of regulatory services and electronic platforms for pharmaceutical and medical device oversight. The EDA's core product portfolio includes the Egyptian Pharmacopoeia (official pharmaceutical reference with 5th edition containing 3,000+ monographs), supported by numerous electronic services including the Digital Platform for Protocol Management and Clinical Trials, drug search databases, medical device portals (MeDevice, EGYCOSMA), pharmacovigilance systems (EVERS), batch release systems, and inspection report portals. The EDA also operates a Center for Continuous Professional Development providing training programs for pharmaceutical professionals regionally and internationally. The organization is structured around central administrations covering pharmaceutical products, biological products, medical devices, pharmaceutical care, drug control, and pharmaceutical institution licensing.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Registration and Licensing Services

Quantifiable outcome

• 91% pharmaceutical self-sufficiency achieved in Egypt
• +1 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

20 partnerships are on record, tiered core, minor and major.

• Pharmacy Board of Sierra LeonecoreStrategic or Co-development Partner · 20 June 2026MoU signed at Africa Health ExCon 2026 to enhance bilateral cooperation in pharmaceutical regulation, technical expertise exchange, and capacity building covering drug registration, regulatory inspections, pharmacovigilance, and workforce development.
• Somalia National Medicines Regulatory Authority (NMRA)coreStrategic or Co-development Partner · 20 June 2026MoU signed at Africa Health ExCon 2026 to strengthen cooperation in pharmaceuticals, biological products, and medical devices regulation, including expertise exchange, regulatory best practices, pharmacovigilance, product registration, and capacity-building programs.
• Danish medical device companiesminorGTM or Marketing Partner · 20 June 2026Discussions with Danish delegation of medical device and supplies companies to explore joint cooperation and investment opportunities, focusing on regulatory modernization, technology transfers, and local manufacturing.
• Africa CDCcoreStrategic or Co-development Partner · 15 June 2026Agreements signed for Egypt to host operational headquarters of African Pool Procurement Mechanism (APPM) and formally join continental health initiative, enabling leadership role in African pharmaceutical procurement coordination.
• Algeria National Agency for Pharmaceutical ProductsmajorStrategic or Co-development Partner · 15 June 2026MoU signed to establish cooperation in pharmaceutical products and medical supplies between Egyptian and Algerian regulatory authorities.
• South Africa Health Products Regulatory Authority (SAHPRA)coreStrategic or Co-development Partner · 15 June 2026Launch of pilot joint assessment project for regulatory cooperation between Egyptian and South African authorities, activated through signed MoU.
• Ghana Food and Drugs AuthoritycoreStrategic or Co-development Partner · 19 May 2026Reception of Ghana FDA CEO to strengthen bilateral regulatory cooperation, building on EDA's WHO ML3 achievement and positioning as model regulatory authority in Africa.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 19 May 2026High-level participation in WHO event in Geneva on African pharmaceutical integration, advancing regulatory cooperation and continental drug security goals through AMA-WHO partnership.
• Sweden Medical Products Agency (MPA)coreStrategic or Co-development Partner · 2 May 2026Technical cooperation discussions focused on Egypt attaining WHO Maturity Level 4 (ML4) regulatory status, with Sweden providing regulatory expertise through MPA to support Egypt's goal of becoming regional pharmaceutical hub.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 30 April 2026WHO designated EDA's CPD Center as regional training hub for biomanufacturing in Eastern Mediterranean region, supporting local vaccine and biotherapeutic production capabilities.
• AstraZenecaminorStrategic or Co-development Partner · 18 November 2025Discussion of market stability and strategies to enhance pharmaceutical system with multinational company representatives.
• SandozminorStrategic or Co-development Partner · 18 November 2025Discussion of market stability and strategies to enhance pharmaceutical system with multinational company representatives.
• SanofiminorStrategic or Co-development Partner · 18 November 2025Discussion of market stability and strategies to enhance pharmaceutical system with multinational company representatives.
• PfizerminorStrategic or Co-development Partner · 18 November 2025Discussion of market stability and strategies to enhance pharmaceutical system with multinational company representatives.
• RocheminorStrategic or Co-development Partner · 18 November 2025Discussion of market stability and strategies to enhance pharmaceutical system with multinational company representatives.
• Saudi Food and Drug Authority (SFDA)coreStrategic or Co-development Partner · 25 October 2025Bilateral meeting at ICMRA Summit in Amsterdam to review cooperation progress and discuss opportunities for enhanced regional regulatory coordination with emphasis on digital transformation and artificial intelligence.
• Sierra Leone Pharmacy BoardcoreStrategic or Co-development Partner · 24 September 2025MoU signed to strengthen cooperation in pharmaceutical regulation, capacity building, and technical expertise exchange covering drug registration, inspections, and regulatory oversight including training programs.
• German University in CairominorStrategic or Co-development PartnerAcademic partnership for biomanufacturing training programs supporting WHO-designated training centre activities.
• United States Pharmacopeia (USP)coreStrategic or Co-development PartnerCooperation agreement for expertise exchange, EDA hosted USP conferences in Egypt, with EDA obtaining full membership in USP Convention with voting rights.
• African Medicines Agency (AMA)coreStrategic or Co-development PartnerPartnership with African Medicines Agency and WHO for advancing African pharmaceutical regulatory integration and continental drug security.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Tanzania Medicines and Medical Devices Authority (TMDA): TMDA is one of the first African regulators to achieve WHO ML3 status and serves as a model for EDA's own ML3 trajectory. Both authorities regulate pharmaceuticals and medical devices at national level and collaborate on regional harmonization efforts, giving them closely aligned regulatory functions and development paths.
• Saudi Food and Drug Authority (SFDA): SFDA is the national pharmaceutical and medical device regulator of Saudi Arabia and EDA's most direct regional counterpart. Both agencies oversee drug registration, medical devices, and biologics for large MENA markets, share Arabic-language regulatory infrastructure, and engage bilaterally through forums like ICMRA summits—making SFDA EDA's closest operating peer.
• South African Health Products Regulatory Authority (SAHPRA): SAHPRA is Africa's most mature national regulator and EDA's declared joint-assessment partner. Both regulators oversee pharmaceutical, biological, and medical device approvals across large national markets and compete to lead African regulatory harmonization under the African Medicines Agency framework—EDA is already running a pilot joint assessment with SAHPRA.
• Ghana Food and Drugs Authority (FDA Ghana): Ghana FDA is West Africa's leading national regulator and a frequent EDA cooperation partner. Both agencies oversee drug registration, inspections, and pharmacovigilance across English-speaking African markets and collaborate on harmonization efforts within the African Medicines Agency initiative—making Ghana FDA a directly comparable peer in scope and stage.
• National Agency for Food and Drug Administration and Control (NAFDAC, Nigeria): NAFDAC is the regulator for Africa's largest pharmaceutical market and a key African Medicines Agency stakeholder. Like EDA, NAFDAC oversees drug registration, manufacturing inspections, and pharmacovigilance for a high-volume domestic market, making it a direct peer competing for continental regulatory leadership.

Broad incumbents

• European Medicines Agency (EMA): EMA sets the regulatory standards against which EDA benchmarks through its observer status in the European Pharmacopoeia Commission and GEON associate membership. As a supranational regulator covering 27 EU markets with mature evaluation and pharmacovigilance systems, EMA is the broad incumbent EDA most directly aspires to align with operationally.
• Central Drugs Standard Control Organization (CDSCO, India): CDSCO is the regulator behind the world's largest pharmaceutical manufacturing base and serves as the benchmark for an emerging market that leveraged domestic pharma scale into global export dominance. Directly relevant as EDA aims to similarly scale Egypt's pharma industry, which already contributes >50% of Africa's exports.
• Brazilian Health Regulatory Agency (ANVISA): ANVISA is an emerging-market regulator of comparable scale and ambition, overseeing pharmaceuticals, medical devices, and biologics across a large continental market. While broader in mandate than EDA and more mature, ANVISA offers a relevant benchmark for an emerging-market regulator pursuing continental regulatory influence.
• US Food and Drug Administration (FDA): The US FDA is the global gold standard for pharmaceutical and medical device regulation and connects to EDA via EDA's full membership in the US Pharmacopeia Convention (with voting rights). Though vastly larger and broader in mandate, the FDA is the ultimate reference regulator for EDA's ML3/ML4 trajectory and global standards setting.

Emerging players

• National Pharmaceutical Regulatory Agency (NPRA, Malaysia): NPRA is a Muslim-majority emerging-market regulator that has successfully built WHO-recognized pharmaceutical oversight and serves as a peer for EDA's modernization agenda. Comparable in scope (drug registration, biologics, medical devices) and in targeting export-oriented pharmaceutical manufacturing for its jurisdiction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedIneg.linkedin.com/company/egyptian-drug-authority
• Facebookfacebook.com/egyptiandrugauthority

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egyptian Drug Authority